X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology,
X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology, includingultrasound detection of pulmonary embolism and myocardial ischemia.The agreement also includes global sales and marketing of productsbased on the technology.
Interactive Medical Technologies has developed albumin-basedmicrospheres, which can be manufactured in sizes as small as onemicron. Under the terms of the agreement, E-Z-EM will begin preclinicalsafety testing of the microspheres at Dartmouth Medical Schoolin Hanover, NH, and the company will also analyze the regulatorycosts for conducting additional clinical trials.
"E-Z-EM is especially interested in this unique technologyas it could relate to various imaging applications in our targetmarkets," said E-Z-EM president and CEO Daniel Martin. "Contrastmicrospheres could have applications in enhancing the measurementof blood flow by ultrasound."
In other E-Z-EM news, the company in February introduced anew barium sulfate contrast agent for CT exams of the abdomenand pelvis. The new product will be marketed as E-Z-CAT Dry.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.